Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1

NCT01216696 is registered in ClinicalTrials.gov with National Center for Tumor Diseases, Heidelberg as lead sponsor.

NCT NCT01216696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01216696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1
Lead sponsor
National Center for Tumor Diseases, Heidelberg
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
August 31, 2016
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma